Gastroenterology
Targeting Oncomucin-Driven Immunosuppression Improves KRAS G12D Inhibition in Pancreatic Cancer
By MedXY|May 28, 2026
Oncomucins such as MUC4 and MUC16 help pancreatic cancer evade immunity through EGFR/UNC5B signaling. Targeting these mucins may enhance KRAS G12D inhibitor efficacy and reduce tumor burden.